News AZ claims EU okay for Imfinzi in bladder cancer AstraZeneca passes another milestone in its journey to rebuild Imfinzi's presence in bladder cancer, a key growth driver for the drug.
News FDA loosens restrictions on first-gen CAR-T therapies There is enough experience with the first wave of autologous CAR-T therapies to allow strict rules ensuring their safe use to be relaxed, says FDA.
News BioNTech to buy rival mRNA firm CureVac for $1.25bn BioNTech has agreed to buy another specialist in mRNA medicines, fellow German biotech CureVac, for around $1.25 billion.
News ASCO 25: Jazz, PharmaMar reveal SCLC survival data Jazz and PharmaMar have revealed the overall survival data with their small-cell lung cancer drug Zepzelca, described as a 'milestone' in the disease.
News UK trumpets £1bn investment plan from BioNTech BioNTech has said it will commit up to £1bn in investment in the UK over the next decade, in what has been described as a "template" for the sector.
News Pfizer snaps up PD-1/VEGF drug from China's 3SBio Pfizer has joined the ranks of those developing cancer drugs that target PD-1 and VEGF, penning a $6bn licensing deal with China's 3SBio.
News AZ prepares to file blood pressure drug after trial win Two years after buying CinCor for $1.3 billion, AstraZeneca has reported that the main asset in the deal has cleared a phase 3 trial.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
